Log in

NASDAQ:APTX - Aptinyx Stock Price, Forecast & News

$2.16
-0.16 (-6.90 %)
(As of 04/1/2020 04:49 AM ET)
Today's Range
$2.07
Now: $2.16
$2.38
50-Day Range
$1.81
MA: $2.84
$3.72
52-Week Range
$1.60
Now: $2.16
$5.25
Volume162,855 shs
Average Volume319,854 shs
Market Capitalization$94.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Read More
Aptinyx logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTX
CUSIPN/A
CIKN/A
Phone847-871-0377

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.57 million
Book Value$4.46 per share

Profitability

Net Income$-53,280,000.00
Net Margins-1,523.09%

Miscellaneous

EmployeesN/A
Market Cap$94.71 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter.


Aptinyx (NASDAQ:APTX) Frequently Asked Questions

How has Aptinyx's stock been impacted by COVID-19 (Coronavirus)?

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APTX stock has decreased by 11.1% and is now trading at $2.16. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aptinyx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptinyx.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Aptinyx.

How were Aptinyx's earnings last quarter?

Aptinyx Inc (NASDAQ:APTX) posted its quarterly earnings results on Monday, March, 30th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.15. The business earned $0.92 million during the quarter, compared to the consensus estimate of $0.95 million. Aptinyx had a negative return on equity of 44.24% and a negative net margin of 1,523.09%. View Aptinyx's earnings history.

What price target have analysts set for APTX?

5 analysts have issued 1 year price objectives for Aptinyx's shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate Aptinyx's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 339.8% from the stock's current price. View analysts' price targets for Aptinyx.

Has Aptinyx been receiving favorable news coverage?

News articles about APTX stock have been trending very negative on Wednesday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAptinyx.

Are investors shorting Aptinyx?

Aptinyx saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 229,400 shares, an increase of 14.6% from the February 27th total of 200,100 shares. Based on an average daily trading volume, of 180,400 shares, the short-interest ratio is currently 1.3 days. Currently, 1.7% of the company's shares are short sold. View Aptinyx's Current Options Chain.

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:
  • Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
  • Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
  • Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
  • Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)

When did Aptinyx IPO?

(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $2.16.

How big of a company is Aptinyx?

Aptinyx has a market capitalization of $94.71 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.  View additional information about Aptinyx.

What is Aptinyx's official website?

The official website for Aptinyx is http://www.aptinyx.com/.

How can I contact Aptinyx?

Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]


MarketBeat Community Rating for Aptinyx (NASDAQ APTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  106 (Thanks for Voting!)
Underperform Votes:  93 (Thanks for Voting!)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: What is a Roth IRA?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel